Adam Colborn, JD

Abandoning efforts to reform payment for cell and gene therapies for Medicaid beneficiaries could allow ongoing access barriers to persist, said Adam Colborn, JD, of AMCP.

Adam Colborn, JD, of AMCP, discusses the complexities of drug pricing and what policymakers must consider in efforts to reduce prices and increase access.

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.